🇺🇸 FDA
Pipeline program

Oral hexavalent reassortant rotavirus attenuated live vaccine

PRO-RV-1001

Phase 2 mab active

Quick answer

Oral hexavalent reassortant rotavirus attenuated live vaccine for Rotavirus Gastroenteritis is a Phase 2 program (mab) at SINOVAC BIOTECH LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
SINOVAC BIOTECH LTD
Indication
Rotavirus Gastroenteritis
Phase
Phase 2
Modality
mab
Status
active

Clinical trials